Axsome Therapeutics, Inc.

AXSM

US05464T1043

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Sector

Pharmaceuticals

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Axsome Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

75.94 USD

Average target price

122.7 USD

Spread / Average Target

+61.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AXSOME THERAPEUTICS, INC.	-4.59%	3.55B
CSL LIMITED	-3.07%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-14.43%	31.67B
UCB	+51.20%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.85%	15.65B
INCYTE CORPORATION	-13.87%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-7.87%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-39.40%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+5.62%	8.81B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-06 EDT			5-day change	1st Jan Change
75.94 ^USD	+1.52%		+3.05%	-4.59%

05-06	Transcript : Axsome Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024
05-06	Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell	MT

Transcript : Axsome Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024	05-06
Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell	05-06	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M	05-06	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	05-06	DJ
North American Morning Briefing : More Earnings -2-	04-30	DJ
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says	04-29	MT
Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90	04-29	MT
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	04-02	MT
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	04-01	CI
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating	03-28	MT
HC Wainwright Adjusts Axsome Therapeutics' Price Target to $190 From $180, Keeps Buy Rating	03-26	MT
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating	03-26	MT
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating	03-26	MT
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	03-25	MT
Transcript : Axsome Therapeutics, Inc. - Special Call	03-25
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	03-25	CI
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	03-25	RE
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	03-25	CI
Baird Initiates Axsome Therapeutics With Outperform Rating, Price Target is $108	03-19	MT
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	03-19	CI
Axsome Therapeutics Insider Sold Shares Worth $2,257,449, According to a Recent SEC Filing	03-18	MT
Mizuho Cuts PT on Axsome Therapeutics to $108 From $112 After Release of AD Agitation Study Data Faces Delays, Keeps Buy Rating	02-26	MT
UBS Adjusts Axsome Therapeutics Price Target to $107 From $111, Maintains Buy Rating	02-21	MT
RBC Trims Price Target on Axsome Therapeutics to $123 From $126, Notes 'Disappointing' Delay in Data From ADVANCE-2 Trial; Outperform Kept	02-21	MT